Edward Cox

Has grant

Health Economist

University of Nottingham
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

A randomised controlled trial to evaluate the clinical and cost effectiveness of the Action Falls rehabilitation programme compared to usual care alone to reduce falls in stroke survivors.

Open Date: 2024-09-01

Close Date: 2028-08-31

Articles (6)

Year:

2026

Year:

2024

Year:

2024

Background Cascade testing the relatives of people with familial hypercholesterolaemia is an efficient approach to identifying familial hypercholesterolaemia. The cascade-testing protocol starts with identifying an index patient with familial hypercholesterolaemia, followed by one of three approaches to contact other relatives: indirect approach, whereby index patients contact their relatives; direct approach, whereby the specialist contacts the relatives; or a combination of both direct and indirect approaches. However, it is unclear which protocol may be most effective. Objectives The objectives were to determine the yield of cases from different cascade-testing protocols, treatment patterns, and short- and long-term outcomes for people with familial hypercholesterolaemia; to evaluate the cost-effectiveness of alternative protocols for familial hypercholesterolaemia cascade testing; and to qualitatively assess the acceptability of different cascade-testing protocols to individuals and families with familial hypercholesterolaemia, and to health-care providers. Design and methods This study comprised systematic reviews and analysis of three data sets: PASS (PASS Software, Rijswijk, the Netherlands) hospital familial hypercholesterolaemia databases, the Clinical Practice Research Datalink (CPRD)–Hospital Episode Statistics (HES) linked primary–secondary care data set, and a specialist familial hypercholesterolaemia register. Cost-effectiveness modelling, incorporating preceding analyses, was undertaken. Acceptability was examined in interviews with patients, relatives and health-care professionals. Result Systematic review of protocols: based on data from 4 of the 24 studies, the combined approach led to a slightly higher yield of relatives tested [40%, 95% confidence interval (CI) 37% to 42%] than the direct (33%, 95% CI 28% to 39%) or indirect approaches alone (34%, 95% CI 30% to 37%). The PASS databases identified that those contacted directly were more likely to complete cascade testing ( p < 0.01); the CPRD–HES data set indicated that 70% did not achieve target treatment levels, and demonstrated increased cardiovascular disease risk among these individuals, compared with controls (hazard ratio 9.14, 95% CI 8.55 to 9.76). The specialist familial hypercholesterolaemia register confirmed excessive cardiovascular morbidity (standardised morbidity ratio 7.17, 95% CI 6.79 to 7.56). Cost-effectiveness modelling found a net health gain from diagnosis of –0.27 to 2.51 quality-adjusted life-years at the willingness-to-pay threshold of £15,000 per quality-adjusted life-year gained. The cost-effective protocols cascaded from genetically confirmed index cases by contacting first- and second-degree relatives simultaneously and directly. Interviews found a service-led direct-contact approach was more reliable, but combining direct and indirect approaches, guided by index patients and family relationships, may be more acceptable. Limitations Systematic reviews were not used in the economic analysis, as relevant studies were lacking or of poor quality. As only a proportion of those with primary care-coded familial hypercholesterolaemia are likely to actually have familial hypercholesterolaemia, CPRD analyses are likely to underestimate the true effect. The cost-effectiveness analysis required assumptions related to the long-term cardiovascular disease risk, the effect of treatment on cholesterol and the generalisability of estimates from the data sets. Interview recruitment was limited to white English-speaking participants. <jats:sec id=

Year:

2023

Year:

2023

Year:

2022

Collaborators (11)

Benjamin Maylor

University of Oxford

UNITED KINGDOM
View details

Bethan Sarah Woods

University of York

UNITED KINGDOM
View details

Simon Mark Walker

Professor

University of York

UNITED KINGDOM
View details

Claire Rothery

Professor of Health Economics

University of York

UNITED KINGDOM
View details

Pedro Rafael Saramago Goncalves

Senior Research Fellow

University of York

UNITED KINGDOM
View details

Joe Kai

Head of Division, Primary Care

University of Nottingham

UNITED KINGDOM
View details

David Dunstan

Professor

Australian Catholic University

AUSTRALIA
View details

Nadeem Qureshi

Primary Care lead

University of Nottingham

UNITED KINGDOM
View details

Stuart Biddle

Professor, Physical Activity & Health

University of Southern Queensland

AUSTRALIA
View details

Nick Meader

Principal Research Associate

Newcastle University

UNITED KINGDOM
View details

Stacy Clemes

Professor of Active Living and Public Health

Loughborough University

UNITED KINGDOM
View details